Impact of Crisaborole in Treatment-Experienced Patients with Mild-to-Moderate Atopic Dermatitis
Dermatitis® · 2024
DOI: 10.1089/derm.2023.0112 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Dermatitis®, 2024. Verfasst von Linda F Stein Gold und 6 weiteren Autor:innen. Beteiligte Einrichtung: From the Henry Ford Health System, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Boron Compounds, Dermatitis, Atopic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of patients with mild-to-moderate atopic dermatitis (AD).
Objective
To assess the efficacy and safety of crisaborole in patients with AD who had received prior treatment with ( a ) corticosteroids (systemic or topical) or topical calcineurin inhibitors (TCIs) or ( b ) topical corticosteroids (TCSs) or TCIs or ( c ) who were treatment-naive (TN).
Methods
This post hoc analysis comprised patients aged ≥2 years with mild-to-moderate AD. Patients were assigned (2:1) to receive crisaborole or vehicle twice daily for 28 days. Patient response was assessed with the Investigator's Static Global Assessment (ISGA), Dermatology Life Quality Index (DLQI), Children's Dermatology Life Quality Index (CDLQI), and Dermatitis Family Impact (DFI) tools. Safety was also assessed.
Results
A significantly higher percentage of patients treated with crisaborole versus vehicle achieved ISGA success regardless of treatment history. Patients treated with crisaborole had significant reductions in DLQI, CDLQI, and DFI scores versus those who received vehicle regardless of treatment history, with the exception of DLQI and DFI scores in the TN group. Crisaborole was well tolerated in all subgroups.
Conclusion
Crisaborole demonstrated a favorable efficacy and safety profile in both treatment-experienced and TN patients. ClinicalTrials.gov, NCT02118766 and NCT02118792
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Henry Ford Health System, Detroit, Michigan, USA.
- University of California San Diego and Rady Children's Hospital-San Diego, San Diego, California, USA.
- Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
- Pfizer R&D UK Ltd., Surrey, United Kingdom.
- Pfizer, Inc., Collegeville, Pennsylvania, USA.
- Pfizer, Inc., New York, New York, USA.
Zitieren
APA
Stein Gold, L. F., Tom, W. L., Shi, V., Sanders, P., Zang, C., Vlahos, B., & Cha, A. (2024). Impact of Crisaborole in Treatment-Experienced Patients with Mild-to-Moderate Atopic Dermatitis. Dermatitis®. https://doi.org/10.1089/derm.2023.0112
Vancouver
Stein Gold LF, Tom WL, Shi V, Sanders P, Zang C, Vlahos B, et al. Impact of Crisaborole in Treatment-Experienced Patients with Mild-to-Moderate Atopic Dermatitis. Dermatitis®. 2024. doi:10.1089/derm.2023.0112
BibTeX
@article{SteinGold2024,
author = {Stein Gold, Linda F and Tom, Wynnis L and Shi, Vivian and Sanders, Paul and Zang, Chuanbo and Vlahos, Bonnie and Cha, Amy},
title = {Impact of Crisaborole in Treatment-Experienced Patients with Mild-to-Moderate Atopic Dermatitis},
journal = {Dermatitis®},
year = {2024},
doi = {10.1089/derm.2023.0112}
}
EUVIMED